Bone sialoprotein 1; BNSP; BSPI; Early T-lymphocyte activation 1; ETA-1; Nephropontin; OPN; Osteopontin; Osteopontin-C; Osteopontin-D; Osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein; PSEC0156; SPP-1; Secreted phosphoprotein 1; Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1); SPP1; SPP1/CALPHA1 fusion; Urinary stone protein; Uropontin
The protein product of gene Spp1 is known by many names; however, osteopontin (OPN) is the most widely used and preferred. Osteopontin was first identified in osteoblasts and is primarily known for its role in bone mineralization, hence derives the name “osteo” for bone and pontin from “pons”- bridge in Latin. Orthologous gene analysis of Spp1 gene indicates that it is found in 39 eukaryotic genera. In humans, OPN is expressed in many organs and plays an important role in many cellular, physiological, immunological, and...
NIH R01CA194048 grant to R.S.S.
- Beausoleil MS, Schulze EB, Goodale D, Postenka CO, Allan AL. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. BMC Cancer. 2011;11. doi:10.1186/1471-2407-11-25.Google Scholar
- Florea A-M, Büsselberg D. Breast cancer and possible mechanisms of therapy resistance. J Local Global Health. 2013;2. doi:10.5339/jlghs.2013.2.Google Scholar
- Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4. doi:10.1186/s40169-015-0048-3.Google Scholar
- Katagiri YU, Murakami M, Mori K, Iizuka J, Hara T, Tanaka K, et al. Non-RGD domains of osteopontin promote cell adhesion without involving alpha v integrins. J Cell Biochem. 1996;62:123–31. doi:10.1002/(SICI)1097-4644(199607)62:1<123::AID-JCB13>3.0.CO;2-O.CrossRefPubMedPubMedCentralGoogle Scholar
- Schulze EB, Hedley BD, Goodale D, Postenka CO, Al-Katib W, Tuck AB, et al. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat. 2008;112:243–54. doi:10.1007/s10549-007-9865-4.CrossRefPubMedPubMedCentralGoogle Scholar
- Talbot LJ, Mi Z, Bhattacharya SD, Kim V, Guo H, Kuo PC. Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery. 2011;150:224–30. doi:10.1016/j.surg.2011.05.015.CrossRefPubMedPubMedCentralGoogle Scholar